Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Outlook Therapeutics, Inc.

NASDAQ: OTLK · Life Sciences · 2 alerts · CIK 1649989

Share price
$0.3960Close, Nov 16
Market cap
$96.4M
Shares outstanding
243.45MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Outlook Therapeutics, Inc. filings on SEC EDGAR ↗

4:30 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Outlook Therapeutics Nasdaq/NYSE Compliance Notice

Outlook Therapeutics received a deficiency notice from Nasdaq on September 25, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 calendar days, until March 24, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. If compliance is not met, the company may be eligible for an additional 180-day period or face potential delisting.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days
4:31 PM ET 8-K
Business Update

Outlook Therapeutics Business Update

Outlook Therapeutics has established the wholesale acquisition cost (WAC) for LYTENAVA™ in the United States at $485 per vial. This pricing announcement follows the drug's regulatory progress and sets the commercial baseline for its market entry.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.